Haemonetics Corporation (FRA:HAZ)

Revenue by Geography

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Dec 27, 2025	Mar 29, 2025	Mar 30, 2024	Apr 1, 2023	Apr 2, 2022	Apr 3, 2021	Mar 28, 2020	Mar 30, 2019	Mar 31, 2018	Apr 1, 2017	Apr 2, 2016	Mar 28, 2015	Mar 29, 2014	Mar 30, 2013
United States Revenue	978.50M	1.01B	970.01M
United States Revenue Growth	-3.21%	4.22%	15.08%
Japan Revenue	65.90M	62.41M	58.09M
Japan Revenue Growth	5.60%	7.44%	-5.23%
Europe Revenue	174.40M	175.66M	160.14M
Europe Revenue Growth	-0.71%	9.69%	2.21%
Asia Revenue	88.40M	92.31M	107.54M
Asia Revenue Growth	-4.23%	-14.16%	3.27%
Other Geographic Revenue	11.08M	19.54M	13.28M
Other Geographic Revenue Growth	-43.30%	47.09%	263.62%
Revenue (Total)	1.32B	1.36B	1.31B
Revenue (Total) Growth	-3.13%	3.96%	12.01%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Dec 27, 2025	Mar 29, 2025	Mar 30, 2024	Apr 1, 2023	Apr 2, 2022	Apr 3, 2021	Mar 28, 2020	Mar 30, 2019	Mar 31, 2018	Apr 1, 2017	Apr 2, 2016	Mar 28, 2015	Mar 29, 2014	Mar 30, 2013
Plasma Revenue	520.90M	535.43M	569.54M
Plasma Revenue Growth	-2.71%	-5.99%	13.80%
Blood Center Revenue	220.86M	261.12M	283.23M
Blood Center Revenue Growth	-15.42%	-7.80%	-2.12%
Hospital Revenue	576.51M	564.27M	456.29M
Hospital Revenue Growth	2.17%	23.66%	20.65%
Revenue (Total)	1.32B	1.36B	1.31B
Revenue (Total) Growth	-3.13%	3.96%	12.01%

EBIT

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Dec 27, 2025	Mar 29, 2025	Mar 30, 2024	Apr 1, 2023	Apr 2, 2022	Apr 3, 2021	Mar 28, 2020	Mar 30, 2019	Mar 31, 2018	Apr 1, 2017	Apr 2, 2016	Mar 28, 2015	Mar 29, 2014	Mar 30, 2013
Plasma Segment Operating Income (Post-Q3 2025 Reporting)	-	184.51M	181.97M
Plasma Segment Operating Income (Post-Q3 2025 Reporting) Growth	-	1.40%	45.87%
Blood Center Segment Operating Income (Post-Q3 2025 Reporting)	-	52.82M	42.37M
Blood Center Segment Operating Income (Post-Q3 2025 Reporting) Growth	-	24.65%	-34.07%
Hospital Segment Operating Income (Post-Q3 2025 Reporting)	-	88.98M	52.20M
Hospital Segment Operating Income (Post-Q3 2025 Reporting) Growth	-	70.46%	77.45%
Operating Income (Total)	251.09M	221.82M	164.88M
Operating Income (Total) Growth	13.20%	34.53%	5.67%

EBIT 2

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Dec 27, 2025	Mar 29, 2025	Mar 30, 2024	Apr 1, 2023	Apr 2, 2022	Apr 3, 2021	Mar 28, 2020	Mar 30, 2019	Mar 31, 2018	Apr 1, 2017	Apr 2, 2016	Mar 28, 2015	Mar 29, 2014	Mar 30, 2013
Plasma Segment Operating Income	-	-	309.79M
Plasma Segment Operating Income Growth	-	-	11.20%
Blood Center Segment Operating Income	-	-	109.56M
Blood Center Segment Operating Income Growth	-	-	-17.07%
Hospital Segment Operating Income	-	-	184.18M
Hospital Segment Operating Income Growth	-	-	19.27%
Operating Income (Total)	251.09M	221.82M	164.88M
Operating Income (Total) Growth	13.20%	34.53%	5.67%

Updated Dec 27, 2025. Data Source: Fiscal.ai.